KUBICZKOVÁ, Lenka, Fedor KRYUKOV, Ondřej SLABÝ, Elena Vladimirovna KRYUKOVA, Jiří JARKOVSKÝ, Jana NEKVINDOVÁ, Lenka RADOVÁ, Henrieta GREŠLIKOVÁ, Petr KUGLÍK, Eva VETEŠNÍKOVÁ, Luděk POUR, Zdeněk ADAM, Sabina ŠEVČÍKOVÁ and Roman HÁJEK. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica/the hematology journal. Pavia: Fondazione Ferrata Storti, 2014, vol. 99, No 3, p. 511-518. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2013.093500.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance
Authors KUBICZKOVÁ, Lenka (203 Czech Republic, belonging to the institution), Fedor KRYUKOV (643 Russian Federation, belonging to the institution), Ondřej SLABÝ (203 Czech Republic), Elena Vladimirovna KRYUKOVA (643 Russian Federation, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Jana NEKVINDOVÁ (203 Czech Republic), Lenka RADOVÁ (203 Czech Republic), Henrieta GREŠLIKOVÁ (703 Slovakia, belonging to the institution), Petr KUGLÍK (203 Czech Republic, belonging to the institution), Eva VETEŠNÍKOVÁ (203 Czech Republic), Luděk POUR (203 Czech Republic, belonging to the institution), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Sabina ŠEVČÍKOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Roman HÁJEK (203 Czech Republic, belonging to the institution).
Edition Haematologica/the hematology journal, Pavia, Fondazione Ferrata Storti, 2014, 0390-6078.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Italy
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 5.814
RIV identification code RIV/00216224:14110/14:00075513
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3324/haematol.2013.093500
UT WoS 000336255000022
Keywords in English Multiple myeloma; MGUS; circulating miRNA; miRNA profiling; qPCR
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 9/9/2014 15:10.
Abstract
Multiple myeloma still remains incurable in majority of cases prompting further search for new and better prognostic markers. Emerging evidence has suggested that circulating microRNAs can serve as minimally invasive biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. In this study, a global analysis of serum microRNAs by TaqMan Low Density arrays was performed, followed by quantitative real-time PCR. The analyses revealed five deregulated microRNAs: miR-744, miR-130a, miR-34a, let-7d and let-7e in monoclonal gammopathy of undetermined significance, newly diagnosed and relapsed multiple myeloma when compared to healthy donors. Multivariate logistic regression analysis showed that combination of miR-34a and let-7e can distinguish multiple myeloma from healthy donors with sensitivity 80.6% and specificity 86.7% and monoclonal gammopathy of undetermined significance from healthy donors with sensitivity 91.1% and specificity 96.7%. Furthermore, lower levels of miR-744 and let-7e were associated with shorter overall survival and remission of myeloma patients. One-year mortality rate for miR-744 and let-7e was 41.9% and 34.6% for ’low’ expression and 3.3% and 3.9% for ’high’ expression group, respectively. Median time of remission for both miR- 744 and let-7e was ~11 months for ’low’ expression and ~47 months for ’high’ expression groups of myeloma patients These data demonstrate that expression patterns of circulating microRNAs are altered in multiple myeloma and monoclonal gammopathy of undetermined significance and miR-744 with let-7e are associated with survival of myeloma patients.
Links
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
MUNI/11/InGA17/2012, interní kód MUName: MikroRNA v patogenezi extramedulárního relapsu mnohočetného myelomu
Investor: Masaryk University
NT13190, research and development projectName: Molekulární charakteristika centrozomálních abnormalit a jejich prognostický význam pro pacienty s mnohočetným myelomem
Investor: Ministry of Health of the CR
7E12070, research and development projectName: Optimizing targets and therapeutics in high risk and refractory multiple myeloma (Acronym: OPTATIO)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 25/7/2024 17:00